Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Free Cash Flow (2020 - 2025)

Vivos Therapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$5.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$5.3 million for Q4 2025, down 72.72% from a year ago — trailing twelve months through Dec 2025 was -$17.6 million (down 32.68% YoY), and the annual figure for FY2025 was -$17.6 million, down 32.68%.
  • Free Cash Flow for Q4 2025 was -$5.3 million at Vivos Therapeutics, down from -$4.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$2.2 million in Q4 2021 to a low of -$6.2 million in Q1 2022.
  • The 5-year median for Free Cash Flow is -$4.0 million (2025), against an average of -$4.0 million.
  • The sharpest move saw Free Cash Flow crashed 841.39% in 2021, then skyrocketed 53.3% in 2023.
  • Year by year, Free Cash Flow stood at -$2.2 million in 2021, then tumbled by 44.27% to -$3.2 million in 2022, then grew by 15.62% to -$2.7 million in 2023, then dropped by 13.52% to -$3.1 million in 2024, then tumbled by 72.72% to -$5.3 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$5.3 million, -$4.1 million, and -$4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.